← All trials
NCT05991908
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 19, 2023
- Primary completion
- Oct 30, 2025
- Completion date
- Jun 30, 2026
- First posted
- Aug 15, 2023
- Last posted
- Oct 24, 2023
- Enrollment
- 222
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Jiao Tong UniversityReponsible party - principal investigator
- Zhaxin HospitalOfficial
- Jiao Tong UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.